chufangao/CTO huggingface dataset:
Clinical trial NCT02504203: Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial
Official title: Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial
Acronym: BCGR
Sponsor: Bandim Health Project (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Due to fewer than expected children enrolled and lower than expected overall mortality rate.
Enrollment: 2332.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-11-30
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Clinical trial NCT04203056: Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
Official title: Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
Acronym: APPRAISE
Sponsor: University of California, Los Angeles (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Withdraw of financial support by industry collaborator
Enrollment: 15.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-16
Primary completion date: 2022-10-01
Completion date: 2022-10-01
Plan to share individual participant data: NO
Clinical trial NCT04470427: A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
Official title: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older
Sponsor: ModernaTX, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 30415.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-27
Primary completion date: 2022-12-29
Completion date: 2022-12-29
Baseline population: All randomized participants who received at least 1 dose of treatment.
Plan to share individual participant data: NO
Clinical trial NCT03018730: Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
Official title: An Open Label Study of the Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
Sponsor: Protalix (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 22.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-05-17
Primary completion date: 2019-12-17
Completion date: 2020-01-09
Plan to share individual participant data: NO
Clinical trial NCT05413642: COVID-19 Algorithm Treatment at Home
Official title: Prevention of Hospitalization of Patients With Early COVID-19 by an Anti-inflammatory Drug-based Home-treatment Algorithm:a Three-months, Pragmatic, Cluster Randomized, Open-label, Blinded Endpoint (PROBE) Trial
Acronym: COVER-HOME
Sponsor: Mario Negri Institute for Pharmacological Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Due to changes in the monitoring rules for SARS-CoV-2 and the dramatic reduction in COVID-19 cases, it became extremely difficult to recruit the required number of patients provided by the study protocol to meet the study's primary objective.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-07-01
Primary completion date: 2024-02-06
Completion date: 2024-02-06
Clinical trial NCT03558724: Fluorescence Endoscopy of Esophageal Carcinoma
Official title: Fluorescence Molecular Endoscopy of Locally Advanced Esophageal Carcinoma Using Bevacizumab-800CW to Evaluate Dose Response After Neoadjuvant Chemoradiotherapy: a Single-center Feasibility Study.
Acronym: ORCA
Sponsor: University Medical Center Groningen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Dose-escalation was finished, but no clear correlation between fluorescence and tumor grade was established
Enrollment: 25.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-10-29
Primary completion date: 2022-10-11
Completion date: 2022-10-11
Plan to share individual participant data: NO
Clinical trial NCT04289948: Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes
Official title: Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes
Acronym: PDFI
Sponsor: University Hospitals of Derby and Burton NHS Foundation Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Funding issues meant that development of the study was halted.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-01
Primary completion date: 2022-06-01
Completion date: 2022-09-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04324840: A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma
Official title: A Phase 1b, Open-label, Dose-Finding Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business objectives have changed
Enrollment: 184.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-07-10
Primary completion date: 2024-07-09
Completion date: 2024-07-09
Plan to share individual participant data: YES
IPD sharing description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
IPD time frame: See Plan Description
IPD access criteria: See Plan Description
Clinical trial NCT05229900: A Study of SGN-ALPV in Advanced Solid Tumors
Official title: A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
Sponsor: Seagen Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study closed due to portfolio prioritization
Enrollment: 43.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-04-21
Primary completion date: 2023-12-13
Completion date: 2023-12-13
Clinical trial NCT03173963: Empaglifozin in Early Diabetic Kidney Disease
Official title: Empagliflozin in Early Diabetic Kidney Disease
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Original drug sponsor withdrew from study, replacement sponsor not obtained.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-27
Primary completion date: 2020-02-21
Completion date: 2020-02-21
Clinical trial NCT03743194: Pectoralis and Serratus Muscle Blocks
Official title: Pectoralis and Serratus Muscle Blocks for Analgesia After Minimally Invasive Cardiac Procedures
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 210.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-14
Primary completion date: 2022-02-28
Completion date: 2022-03-14
Clinical trial NCT05201001: APX005M in Patients With Recurrent Ovarian Cancer
Official title: An Early Phase Randomized Trial of APX005M in BRCAwt Patients With Recurrent Ovarian Cancer
Acronym: APX005M
Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: IMP provider company (Apexigen) is sold, thus both IMP and grant is terminated
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-09-07
Primary completion date: 2023-09-07
Completion date: 2023-09-07
Plan to share individual participant data: UNDECIDED
IPD sharing description: NSGO-CTU can be contacted
Clinical trial NCT04051801: Multiple Ascending Dose Putative Cognitive Enhancer VU319
Official title: Multiple Ascending Dose Phase I Study of the M1 Positive Allosteric Modulator VU0467319
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Further development has been outlicensed to Acadia Pharmaceuticals
Enrollment: 0.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-05-25
Primary completion date: 2021-05-25
Completion date: 2021-05-25
Clinical trial NCT03010865: Sodium Butyrate For Improving Cognitive Function In Schizophrenia
Official title: Sodium Butyrate As A Treatment For Improving Cognitive Function In Schizophrenia
Sponsor: Shanghai Mental Health Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: sponsor withdrew the funds because the smell of sodium butyrate made blinding impossible
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-01
Primary completion date: 2019-12-31
Completion date: 2020-02-29
Plan to share individual participant data: UNDECIDED
IPD sharing description: Stanley foundation requests: Based on the terms of your award, Stanley Medical Research Institute (SMRI) now requires submission of the individual patient data from all SMRI funded studies. In order to make the process as efficient as possible and provide a secure location for study data, National Institute of Mental Health (NIMH) is graciously allowing SMRI access to their National Database for Clinical Trials (NDCT) to collect and house data.
Clinical trial NCT04760626: A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
Official title: Effectiveness and Safety of Once Weekly Insulin Icodec Used With DoseGuide Versus Once Daily Basal Insulin Analogues in an Insulin naïve Type 2 Diabetes Population in a Clinical Practice Setting
Acronym: ONWARDS 5
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1085.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-01
Primary completion date: 2022-08-12
Completion date: 2022-08-29
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT03941483: Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery
Official title: A Phase 2 Proof of Concept, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 351.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-11-01
Primary completion date: 2021-07-26
Completion date: 2021-10-20
Baseline population: ASP1128 and Placebo: Full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study treatment.~Observational Cohort: NC negative participants who were enrolled in the observational cohort.
Plan to share individual participant data: YES
IPD sharing description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Clinical trial NCT03679884: Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep
Official title: Multi-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Three Doses, 40-week Extension to Studies ID-078A301 and ID-078A302 to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder
Sponsor: Idorsia Pharmaceuticals Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 804.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-10-09
Primary completion date: 2021-02-22
Completion date: 2021-02-22
Baseline population: These are the participants included in the FAS. The discrepancy with previous table (Participant Flow) is due to 3 subjects on FAS (2 on daridorexant 25 mg and 1 on ex-placebo/ daridorexant 25 mg) not starting DB treatment.
Plan to share individual participant data: NO
Clinical trial NCT02478502: Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer
Official title: Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell
Sponsor: University Hospital, Akershus (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Insufficient recruitment
Enrollment: 14.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-06-30
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Clinical trial NCT04602000: A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection
Official title: A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination With Standard of Care in Outpatients With SARS-CoV-2 Infection
Sponsor: Celltrion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 1642.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-10-05
Primary completion date: 2021-05-21
Completion date: 2021-10-20
Plan to share individual participant data: NO
Clinical trial NCT03298061: Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921
Official title: Mepolizumab Long-term Access Programme for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard-of-care Therapy)
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-04-14
Primary completion date: 2023-02-16
Completion date: 2023-02-16
Clinical trial NCT06119529: A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
Official title: A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending Dose Study of LY3872386 in Healthy Participants, a Multiple-Ascending Dose Study of LY3872386 in Patients With Atopic Dermatitis, and an Open-Label Multiple-Dose Evaluation of the Safety and Tolerability of Prednisone in Healthy Participants.
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Based on emerging nonclinical data, the study was terminated.
Enrollment: 18.0 (ACTUAL)
Number of arms: 4.0
Start date: 2023-11-01
Primary completion date: 2024-04-08
Completion date: 2024-04-08
Plan to share individual participant data: NO
Clinical trial NCT04433078: RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM
Official title: RepurpoSing Old Drugs TO SuppRess a Modern Threat: The STORM Trial
Acronym: STORM
Sponsor: Temple University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No Participants Enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-22
Primary completion date: 2021-04-13
Completion date: 2021-04-13
Plan to share individual participant data: NO
Clinical trial NCT04600323: Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD
Official title: Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD
Sponsor: University of Colorado, Denver (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-01
Primary completion date: 2023-08-30
Completion date: 2023-08-30
Plan to share individual participant data: YES
IPD time frame: At the conclusion of the study, data, which has been stripped of all personal identification information and coded with a number, will be made available to qualified individuals within the scientific community who apply for data use. The results and outcomes of this study will be made generally available by publication and journal articles submitted to PubMed Central in compliance with NIH access guidelines.
Clinical trial NCT03329001: Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule
Official title: An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
Sponsor: Tesaro, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 236.0 (ACTUAL)
Number of arms: 6.0
Start date: 2017-12-04
Primary completion date: 2021-12-30
Completion date: 2023-06-15
Baseline population: Baseline characteristics were presented for Safety Population, all participants who received any amount of niraparib during the PK phase of study.
Plan to share individual participant data: YES
IPD sharing description: GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
IPD time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Clinical trial NCT04167670: Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
Official title: A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy With Oral Vonoprazan 20 mg or Double-Blind Triple Therapy With Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy With Oral Lansoprazole 30 mg Daily in Patients With Helicobacter Pylori Infection
Sponsor: Phathom Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1046.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-12-10
Primary completion date: 2021-03-10
Completion date: 2021-03-18
Baseline population: Randomized Set - All participants randomly assigned to receive study drug regardless of whether or not they received a dose of study drug during the study.
Plan to share individual participant data: NO
Clinical trial NCT02960906: A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
Official title: A Phase 2 BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
Acronym: BIONIKK
Sponsor: Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 200.0 (ACTUAL)
Number of arms: 8.0
Start date: 2017-05-31
Primary completion date: 2021-02-15
Completion date: 2021-02-15
Plan to share individual participant data: NO
Clinical trial NCT02489201: A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer
Official title: A Phase 1B Study of Donafenib Monotherapy in Advanced Oesophageal Cancer Progressing After Chemotherapy
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Corporate policy adjustments
Enrollment: 19.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-07-21
Primary completion date: 2020-10-29
Completion date: 2020-10-29
Clinical trial NCT05028361: Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
Official title: Safety of Simultaneous Versus Sequential Administration of mRNA COVID-19 Vaccines and Quadrivalent Inactivated Influenza (IIV4) in Adults, Adolescents and Children: A Randomized Observer Blinded Study
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 348.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-04
Primary completion date: 2023-03-03
Completion date: 2023-06-15
Plan to share individual participant data: NO
Clinical trial NCT02930941: Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department
Official title: Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department
Sponsor: University of California, Davis (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Terminate due to slow enrollment rate.
Enrollment: 35.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-02-29
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Limitations and caveats: Coronavirus Disease 2019 (COVID-19) pandemic significantly impacted the ability to enroll patients; early termination leading to a small number of patients; single-center study;
Plan to share individual participant data: NO
Clinical trial NCT03403517: Preoperative High Dose Steroids for Liver Resection- Effect on Complications in the Immediate Postoperative Period
Official title: High Dose Steroids for Liver Resection - Effect on Complications and Endothelial Function in the Immediate Postoperative Phase - a Randomized, Doubleblind, Controlled Trial
Acronym: STEREO
Sponsor: Rigshospitalet, Denmark (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 174.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-11
Primary completion date: 2020-08-28
Completion date: 2020-09-28
Clinical trial NCT02911467: Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer
Official title: Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) as a Predictive Biomarker of Response to Androgen Signaling Inhibitors in Castration-Resistant Prostate Cancer
Acronym: MR
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Low Accrual
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-11-08
Primary completion date: 2020-07-20
Completion date: 2020-07-20
Plan to share individual participant data: NO